Midwest Bioprocessing Center, Inc.
Peoria, IL Doing business as MBC Part of Ixamar Biotechnology, L.L.C.
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
NRNVN2FEN719
-
Parent
NRNVN2FEN719
- SAM.gov registration date
- Website
- mwbioprocessing.com
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Tango Biosciences Inc. | Chicago, IL | — |
| Karebay Biochem Inc. | Fredonia, NY | 325199 All Other Basic Organic Chemical Manufacturing |
| Taxis Pharmaceuticals Inc. | South Brunswick Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Z Biotech, LLC | Aurora, CO | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Crestone, Inc. | Boulder, CO | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Midwest Bioprocessing Center, Inc., doing business as MBC, operates as a bioprocessing research and development firm under the National Institutes of Health's Small Business Innovation Research (SBIR) program, functioning as a prime grant recipient focused on fermentation engineering and chemoenzymatic synthesis of specialized carbohydrates for drug discovery and antimicrobial applications. MBC is a for-profit manufacturer headquartered in Peoria, Illinois, and operates as a subsidiary of Ixamar Biotechnology, L.L.C.
MBC's entire recent federal footprint consists of six grants awarded by the National Institute of General Medical Sciences (NIGMS) under the SBIR program, with combined obligated dollars of $7.7 million. The vendor has no federal contract prime awards and serves a single customer agency — NIGMS — across 100% of awards. Recent representative work includes a Phase I SBIR award of $313,770 (September 1, 2026, through February 28, 2027) to develop scalable fermentation systems for producing pseudaminic acids and CMP-activated derivatives, compounds that serve as virulence factors in pathogens including Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Acinetobacter baumannii and function as targets for antimicrobial drug discovery and vaccine development. MBC also holds a Phase I SBIR award of $313,957 (August 13, 2026, through July 31, 2027) under CFDA 93.859 (Biomedical Research and Research Training) to develop bioorthogonal nucleotide sugars for glycan research using chemoenzymatic production methods. Earlier Phase I and Phase II grants awarded in March 2022 focused on production of natural deoxysugars for chemical synthesis of glycosides, with Phase II completing in October 2025. Work is performed in Peoria, Illinois.
MBC does not compete under federal set-aside categories and holds no parent contract vehicles or IDIQs. Two awards face ultimate completion within the next twenty-four months. The vendor's capability focus centers on proprietary E. coli fermentation systems and chemoenzymatic pathways for manufacturing rare, high-cost carbohydrates and nucleotide sugars that serve as research reagents and precursors in drug discovery, glycoengineering, and pathogen detection applications.
SBA capabilities narrative
Production and sales of rare sugars, sugar phosphates, activated sugars chemical reagents and products. Production and sales of thermostable enzymes. Glycodiversification and drug discovery services.
Quick answers
Is Midwest Bioprocessing Center, Inc. registered in SAM.gov?
Yes. Midwest Bioprocessing Center, Inc.'s SAM.gov registration is active through February 25, 2027.
What is Midwest Bioprocessing Center, Inc.'s CAGE code?
Midwest Bioprocessing Center, Inc.'s CAGE code is 8FQW1, and its Unique Entity ID (UEI) is JCEBBQJC8TV5.
What is Midwest Bioprocessing Center, Inc.'s most recent federal award?
Midwest Bioprocessing Center, Inc.'s most recent federal grant award is Production of pseudaminic acids and their CMP-activated derivatives (R43GM165183), from National Institute of General Medical Sciences (NIH), on September 1, 2026.
On GovTribe
See Midwest Bioprocessing Center, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors